Compositions for elastogenesis and connective tissue treatment

ABSTRACT

The present invention describes therapeutic compositions comprising one or more minerals, including trivalent iron, divalent manganese and salts thereof, suitable in facilitating synthesis and deposition of connective tissue matrix, particularly rich of elastin and collagen, and mitogenic potential in human dermal fibroblasts. It also describes the phenomenon in which stimulation of elastogenesis by arterial SMC associates with a net decrease in proliferation of these cell types. The present invention also describes methods of treatment of human skin fibroblasts and arterial smooth muscle cells. The therapeutic compositions of the present invention comprise one or more of trivalent iron or divalent manganese or salts thereof and may be combined with an elastic tissue digest.

RELATED APPLICATIONS

This application is a continuation application of U.S. application Ser.No. 11/062,377 entitled “Compositions for Elastogenesis and ConnectiveTissue Treatment”, filed Feb. 22, 2005, which claims priority to U.S.Provisional Application No. 60/546,682 entitled “Composition ComprisingManganese For Connective Tissue Treatment” filed Feb. 20, 2004, and U.S.Provisional Application No. 60/622,104 entitled “Iron and Elastogenesis”filed Oct. 26, 2004, herein incorporated by reference in theirentireties.

This work was supported by the Canadian Institute of Health Research(grant PG 13920) and by the Stroke Foundation of Ontario, (grant NA4381) and Career Investigator Award, (CI 4198) to AH.

JOINT RESEARCH AGREEMENT

The presently claimed invention was made by or on behalf of the belowlisted parties to a joint research agreement. The joint researchagreement was in effect on or before the date the claimed invention wasmade and the claimed invention was made as a result of activitiesundertaken within the scope of the joint research agreement. The partiesto the joint research agreement are The Hospital for Sick Children andHuman Matrix Sciences, LLC.

BACKGROUND OF THE INVENTION

Elastin is an amorphous protein present in the elastic fibers present insuch tissues as blood vessels, skin, tendons, ligaments, and lungs.Elastic fibers are also present in periodontal micro-ligaments and thosesurrounding hair follicles in the skin. Unlike other fibrous tissueslike collagen, elastin is unique in that it may be stretched to over 150percent of its original length but it can rapidly return to its originalsize and shape. This property of elastin provides tissues thatincorporate it, the required ability to resume their original form afterstretching due to blood flow, breathing, or bending. Like collagenprotein, elastin contains about 30% glycine amino acid residues and isrich in proline. Elastin differs from collagen in that it contains verylittle hydroxyproline and no hydroxylysine. It is particularly rich ofalanine and also contains two unique amino acids isodesmosine anddesmosine.

The extracellular matrix (ECM) of the skin and other connective tissuescomprises of numerous glycosaminoglycans, protoglycans, fibronectin,laminin and collagen and elastic fibers. The resiliency of skin ismaintained by elastic fibers. These ECM components are organized into anetworks of rope-like structures and composed of two major components:an amorphous core, consisting of unique polymeric protein, elastin whichmakes up the bulk (>90%) of the fiber; and the 10-12-nm microfibrilsmade up of several distinct glycoproteins, e.g., fibrillins, fibulinsand microfibril-associated glycoproteins (MAGPs). In arterial wallselastin and microfibrils are organized in the form of multipleconcentrated membranes, that are responsible for arterial resiliency.Elastic fiber formation (elastogenesis) is a complex process involvingseveral intracellular and extracellular events. Cells (fibroblasts,endothelial cells, chondroblasts or vascular smooth muscle cells) mustfirst synthesize and secrete numerous glycoproteins to form amicrofibrillilar scaffold. In these cells tropoelastin is synthesized byribosomes in the rough endoplasmatic reticulum and transported throughthe Golgi apparatus and secretory vesicles. Tropoelastin, the solubleprecursor peptide of elastin, with a molecular weight in the range of70-75 kDa, is properly assembled and covalently cross-linked to form theunique composite amino acids called desmosines and isodesmosines bylysyl oxidase into a resilient polymer, insoluble elastin. Production ofelastin reaches its highest levels in the third trimester of the fetallife and steadily decreases during early postnatal development. Inundisturbed tissues elastic fibers may last over the entire humanlifespan. Mature (insoluble) elastin is metabolically inert and remainsthe most durable element of extracellular matrix, that may last for thelifetime in the undisturbed tissues.

The net deposition of elastin appears to be controlled on both thetranscriptional level (tropoelastin mRNA message expression)and-post-transcriptional level (tropoelastin message stability). Thereare also several other post-transcriptional events, which controlsecretion of tropoelastin monomers and their proper extracellularassembly and regulate the cross-linking of tropoelastin into thepolymeric “insoluble” elastin, the most durable element of theextracellular matrix.

In various tissue or biological functions, non-elastic collagen fibersmay be interwoven with the elastin to limit stretching of the elastinand prevent tearing of elastin comprising tissue. However, in contrastto life-long-lasting elastin, collagens which half life differs frommonths to years, have to be periodically replaced.

Different components of the extracellular matrix have been solubilizedand previously incorporated into cosmetic compositions. Because normallycross-linked and highly hydrophobic elastin is insoluble in water,organic solvents, and physiological fluids, more radical chemical andenzymatic methods have to be used to cleave insoluble elastin protein toform smaller peptide fragments, that may be eventually used for cosmeticformulations.

The human skin consists of two layers; a superficial layer called theepidermis which is epithelial tissue and a deeper layer called thedermis that is primarily connective tissue. These two layers are boundtogether to form skin which varies in thickness from less than about 0.5mm, to 3 or even 4 millimeters. The connective tissue found in skin isessentially an intricate meshwork of interacting, extracellularmolecules that constitute the so-called “extracellular matrix” (ECM).Particular components of the ECM (proteoglycans and proteins) aresecreted by local fibroblasts and eventually form the dermal meshworkthat not only mechanically support the cells and blood vessels, but alsomodulate the proper hydration of the skin. Exposure of the skin toultraviolet and visible light from the sun, wind, and certain chemicalsmay cause loss of moisture and structural damage of the existing ECM,that eventually lead to lack of elasticity local collapses (wrinkles) ofthe dermal tissue supporting epidermal layers. Severe loss of elasticityoccurs in response to degradation of the elastic fibers and the factthat in contrast to other ECM components they can not be quicklyreplaced by local “unstimulated” cells. These clinically observedsymptoms, characterized by a lose of normally assembled elastic fibersand accumulation of amorphous and often calcified “clumps” in thedermoepidermal junction and papillary dermis is commonly referred to assolar elastosis.

Until recently, elastin, the major component of elastic fibers, wasthought to have primarily a mechanical role in providing tissueresiliency. This view was challenged by results of in vitro studiesindicating that soluble fragments of tropoelastin and elastindegradation products may bind to the cell surface Elastin BindingProtein (EBP) and stimulate proliferation and migration of human skinfibroblasts, lymphoblasts, smooth muscle cells and cancer cells.

In addition to primary elastinopathies that have been directly linked toalterations in the elastin gene (supravalvular aortic stenosis (SVAS),Williams-Beuren syndrome (WBS) and cutis laxa), a number of secondaryelastinopathies have been described, caused by functional imbalance ofother structural and auxiliary factors regulating elastic fiberdeposition (Marfan disease, GM-1-gangliosidosis, Morquio B, Hurlerdisease, Costello syndrome, Ehlers Danlos syndrome, pseudoxanthomaelasticum (PXE)). A lack of elastin or genetic abnormalities affectingelastic fibers in skin, as evidenced in Costello Syndrome, Cutis Laxaand Pseudoxanthoma Elasticum respectively, lead to premature aging mostnoticeably characterized by wrinkling and folding of the skin inchildren (pre-teenage) suffering from these illnesses. Given that theseconditions only affect elastic fibers in skin, it is highly probablethat development of wrinkles in aged skin is due to damage to or loss ofelastic fibers in skin. Unfortunately, dermal fibroblasts lose theirability to make elastin (the major component of elastic fibers) by theend of puberty. Hence, adult dermal fibroblasts cannot repair or replacedamaged elastic fibers in skin later in life, leading to an essentiallyirreversible formation of wrinkles.

Diffuse elastic fiber defects, resembling those reported in inheritedPXE have also been detected in patients with β-thalassaemia and sicklecell anemia, and in other hemolytic anemias. Genetic basis for thesediseases cannot be directly linked to any structural or regulatorycomponents involved in elastic fiber production. However, it has beensuggested that the accumulation of iron in these patients, resultingfrom hemolysis, increased iron absorption, and multiple bloodtransfusions may lead to acquired elastic tissue defects.

Iron is a physiologically essential nutritional element for all lifeforms. It plays critical roles in electron transport and cellularrespiration, oxygen transport by hemoglobin, cell proliferation anddifferentiation. It has been shown that modulating intracellular ironlevels may also affect expression of numerous genes that are notdirectly involved in iron metabolism, such as protein kinase C-β(PKC-β), an important component of intracellular signaling pathways, orthose encoding extracellular matrix (ECM) components. It has beendemonstrated that dietary iron overload in rats resulted in an increasein the steady-state level of pro-α2(I)-collagen in hepatocytes, and that50 μM iron treatment stimulated collagen gene expression in culturedstromal hepatic cells, by inducing the synthesis and binding of Sp1 andSp3 transcription factors to two regulatory elements located in thecollagen α1 (I) promoter region. On the other hand, iron loading incultured cardiac myocytes and fibroblasts decreased the expression ofTGF-β, biglycan, and collagen type I mRNA, while it facilitated theexpression of decorin mRNA. Interestingly, iron deprivation exerted asimilar effect, suggesting that the expression of these genes involvedin extracellular matrix production is regulated by certainiron-dependent mechanisms.

The molecular basis of iron-dependent mechanism(s) regulating theexpression of ECM encoding genes are not well understood. Since raisinglevels of iron may overwhelm the iron-binding capacity of transferrin,resulting in the appearance of non-transferrin bound iron (NTBI), whichis capable to catalyze the formation of the hydroxyl radicals (throughthe Fenton and Haber-Weiss reactions), it has been suggested thatiron-dependent induction of reactive oxygen species (ROS) may modulatethe transcription of these genes. The possibility of iron-dependentoxidative damage to elastic fibers has also been suggested, but notproven.

Manganese is an essential trace nutrient in all forms of life. Theclasses of enzymes that have manganese cofactors are very broad andinclude such classes as oxidoreductases, transferases, hydrolases,lyases, isomerases, ligases, lectins, and integrins. The best knownmanganese containing polypeptides may be arginase, manganese containingsuperoxide dismuates, and the diptheria toxin.

It has been found that certain minerals and therapeutic compositionscontaining the same can increase synthesis of elastin. In particular,such minerals can stimulate proliferation of (normally dormant)fibroblasts derived from adult human skin and induce synthesis ofelastin and collagen in human fibroblasts and smooth muscle cells. Theseminerals may also induce synthesis of tropoelastin, deposition ofinsoluble elastin, and increase elastin mRNA levels. Stimulation ofcellular rejuvenation may be enhanced by administering a therapeuticcomposition comprising divalent manganese, trivalent iron and saltsthereof.

SUMMARY OF THE INVENTION

One embodiment of the present invention is to provide therapeuticcompositions to stimulate proliferation of fibroblasts and inducesynthesis and deposition of connective tissue proteins, with thespecific and prevalent stimulation of production of normal elasticfibers by human dermal fibroblasts and human arterial smooth musclecells.

Another embodiment of the present invention is to provide therapeuticcompositions to stimulate synthesis of tropoeleastin and deposition ofinsoluble elastin by human dermal fibroblasts.

Another embodiment of the present invention is to provide therapeuticcompositions to increase levels of elastin mRNA levels.

Another embodiment of the present invention relates to therapeuticcompositions comprising one or more divalent manganese based compoundsor salts thereof. Another embodiment of the present invention relates totherapeutic compositions comprising manganese, manganese acorbate,manganese-PCA, manganese chloride, manganese nitrate, manganese sulfateor manganese gluconate or combinations thereof. The salts may be usedseparately or in combinations with an elastic tissue digest, including,but not limited to retinoic acid, or other additives. The compositionsmay be formulated into an emulsion, lotion, spray, aerosol, powder,ointment, cream, mouthwash, toothpaste, foam, gel, shampoo, solution, orsuspension.

Another embodiment of the present invention relates to therapeuticcompositions comprising trivalent iron based compounds or salts thereof.Such iron based compounds include, but are not limited to ferricammonium citrate or ferric chloride. The iron and salts may be usedseparately or in combination with an elastic tissue digest, including,but not limited to retinoic acid, or other additives. The compositionsmay be formulated into an emulsion, lotion, spray, aerosol, powder,ointment, cream, mouthwash, toothpaste, foam or gel.

Another embodiment of the present invention is a therapeutic skin careproduct comprising a therapeutic composition of trivalent iron, divalentmanganese or salts thereof.

Another embodiment of the present invention is a method for clinicallytreating facial lines and wrinkles of a patient comprising providing acomposition comprising one or more of trivalent iron based compounds,divalent manganese based compounds or salts thereof. The compositionprovided to a site presenting visible lines or wrinkles may comprisemanganese-PCA or manganese chloride. The composition provided to a sitepresenting visible lines or wrinkles may comprise a trivalent iron basedcompound, including, but not limited to, ferric ammonium citrate orferric chloride. The compositions may further comprise an elastic tissuedigest.

Another embodiment of the present invention is a method of treating anelastin containing tissue, the method comprising administering to a sitein need thereof on a mammal an effective amount of a compositioncomprising divalent manganese or salts thereof, for improving theelasticity or appearance of said tissue. The composition administered toa tissue may comprise manganese-PCA, or manganese chloride.

Another embodiment of the present invention is a method of treating anelastin containing tissue, the method comprising administering to a sitein need thereof on a mammal an effective amount of a compositioncomprising a trivalent iron or salts thereof, for improving theelasticity or appearance of said tissue.

Another embodiment of the present invention is a method of stimulatingproduction of insoluble elastin in the tissue to which a therapeuticcomposition is administered. Another embodiment of the present inventionis a method of stimulating the endogenous synthesis and deposition ofelastin in the tissue to which a therapeutic composition isadministered. Another embodiment of the invention is a method ofstimulating the deposition of collagen in the tissue to which atherapeutic composition is administered. Another embodiment of thepresent invention is a method of stimulating cell proliferation in thetissue to which a therapeutic composition is administered. Anotherembodiment of the invention is a method of improving the appearance oftissue presenting visible lines or wrinkles or scar tissue.

In a further embodiment, a composition comprising desferrioxamine foruse in treating skin damage in patients with iron overload is provided.

In part, other aspects, features, benefits and advantages of theembodiments of the present invention will be apparent with regard to thefollowing description and appended claims.

BRIEF DESCRIPTION OF THE DRAWINGS

The file of this patent contains at least one photograph or drawingexecuted in color. Copies of this patent with color drawing(s) orphotograph(s) will be provided by the Patent and Trademark Office uponrequest and payment of the necessary fee.

FIG. 1 is an immunohistochemical analysis of elastin synthesis in normalhuman dermal fibroblasts cultures stimulated with compositionembodiments of the present invention.

FIG. 2 is a metabolic labeling of newly deposited insoluble elastin inhuman dermal fibroblast cultures stimulated with composition embodimentsof the present invention.

FIG. 3 is an immunohistochemical analysis of collagen type I levels inhuman dermal fibroblasts stimulated with composition embodiments of thepresent invention.

FIG. 4 is a DNA and [³H]-thymidine incorporation analysis of compositionembodiments of the present invention.

FIG. 5 is a northern blot of elastin mRNA levels in human aortic smoothmuscle cells stimulated with composition embodiments of the presentinvention.

FIG. 6 illustrates deposition of insoluble elastin, the proliferation ofhuman aortic smooth muscle cells, and the deposition of elastic fibersin the extracellular matrix for composition embodiments of the presentinvention.

FIG. 7(A): representative photomicrographs of confluent culturesimmunostained with anti-elastin antibody; FIG. 7(B): quantitative assayof insoluble elastin deposition; FIG. 7(C): assessment of [³H]-thymidineincorporation demonstrates that cells treated with high doses of iron(100 μM and 200 μM) proliferate with a significantly higher rate thanuntreated cells.

FIG. 8(A): results of quantitative assay of newly produced,metabolically labeled and immunoprecipitable soluble tropoelastin; FIG.8(B): Northern blots and TaqMan real time PCR analysis of fibroblastsexposed to iron; FIG. 8(C): mRNA stability in human skin fibroblastcultures

FIG. 9(A): photomicrographs of confluent cultures immunostained withanti-elastin antibody; FIG. 9(B): quantitative assay of insolubleelastin after metabolic labeling; FIG. 9(C): one-step RT-PCR analysisassessing elastin and β-actin mRNA transcripts in cultures.

FIG. 10(A): micrographs of fibroblasts with various iron concentrations;FIG. 10(B): flow cytometric analysis of fibroblasts.

FIG. 11(A): representative photomicrographs of cultured fibroblastsimmunostained with anti-elastin antibody; FIG. 11(B): results ofquantitative assay of insoluble elastin (metabolically labeled).

FIG. 12: a depiction of two parallel iron-dependent mechanisms thatmodulate elastin mRNA levels and consequently affect the net productionof elastin.

FIG. 13: transversal sections of skin biopsy maintained in organ culturefor 7 days in the presence and absence of 10 μM MnSO₄ and 20 μM FAC.

FIG. 14: representative histological sections from a skin biopsy derivedfrom a 45 year-old female in the presence or absence of 10 μM MnSO₄ and20 μM FAC for 7 days.

DETAILED DESCRIPTION OF THE INVENTION

Before the present compositions and methods are described, it is to beunderstood that this invention is not limited to the particularmolecules, compositions, methodologies or protocols described, as thesemay vary. It is also to be understood that the terminology used in thedescription is for the purpose of describing the particular versions orembodiments only, and is not intended to limit the scope of the presentinvention which will be limited only by the appended claims.

It must also be noted that as used herein and in the appended claims,the singular forms “a”, “an”, and “the” include plural reference unlessthe context clearly dictates otherwise. Thus, for example, reference toa “cell” is a reference to one or more cells and equivalents thereofknown to those skilled in the art, and so forth. Unless definedotherwise, all technical and scientific terms used herein have the samemeanings as commonly understood by one of ordinary skill in the art.Although any methods and materials similar or equivalent to thosedescribed herein can be used in the practice or testing of embodimentsof the present invention, the preferred methods, devices, and materialsare now described. All publications mentioned herein are incorporated byreference. Nothing herein is to be construed as an admission that theinvention is not entitled to antedate such disclosure by virtue of priorinvention.

As used herein, the term “about” means plus or minus 10% of thenumerical value of the number with which it is being used. Therefore,about 50% means in the range of 45%-55%. In order that the inventionherein described may be more fully understood, the following detaileddescription is set forth.

The term “cosmetic,” as used herein, refers to a beautifying substanceor preparation which preserves, restores, bestows, simulates, orenhances the appearance of bodily beauty or appears to enhance thebeauty or youthfulness, specifically as it relates to the appearance oftissue or skin.

The term “improves” is used to convey that the present invention changeseither the appearance, form, characteristics and/or the physicalattributes of the tissue to which it is being provided, applied oradministered. The change in form may be demonstrated by any of thefollowing alone or in combination: enhanced appearance of the skin;increased softness of the skin; increased turgor of the skin; increasedtexture of the skin; increased elasticity of the skin; decreased wrinkleformation and increased endogenous elastin production in the skin,increased firmness and resiliency of the skin.

As used herein, the terms “pharmaceutically acceptable”,“physiologically tolerable” and grammatical variations thereof, as theyrefer to compositions, carriers, diluents and reagents, are usedinterchangeably and represent that the materials are capable ofadministration upon a mammal without the production of undesirablephysiological effects such as nausea, dizziness, rash, or gastric upset.In a preferred embodiment, the therapeutic composition is notimmunogenic when administered to a human patient for therapeuticpurposes.

“Providing” when used in conjunction with a therapeutic means toadminister a therapeutic directly into or onto a target tissue or toadminister a therapeutic to a patient whereby the therapeutic positivelyimpacts the tissue to which it is targeted. Thus, as used herein, theterm “providing”, when used in conjunction with compositions comprisingone or more manganese salts, can include, but is not limited to,providing compositions comprising one or more divalent manganese basedcompounds, trivalent iron based compounds or salts thereof into or ontothe target tissue; providing compositions systemically to a patient by,e.g., intravenous injection whereby the therapeutic reaches the targettissue; providing an compositions in the form of the encoding sequencethereof to the target tissue (e.g., by so-called gene-therapytechniques).

Unless otherwise indicated, the term “skin” means that outer integumentor covering of the body, consisting of the dermis and the epidermis andresting upon subcutaneous tissue.

As used herein, the term “therapeutic” means an agent utilized to treat,combat, ameliorate, prevent or improve an unwanted condition or diseaseof a patient. In part, embodiments of the present invention are directedto improve the functionality, the appearance, the elasticity, and/or theelastin content of mammalian tissue. As it applies to skin, it ismeasured by elasticity, turgor, tone, appearance, degree of wrinkles,and youthfulness. As it applies to smooth muscle cells, blood vessels,it is measured by increased elasticity (elastin/elastic fiber synthesisand deposition) and decreased neointimal thickening (smooth muscle cellproliferation). The methods herein for use contemplate prophylactic useas well as curative use in therapy of an existing condition.

The terms “therapeutically effective” or “effective”, as used herein,may be used interchangeably and refer to an amount of a therapeuticcomposition embodiments of the present invention—e.g., one comprisingone or more manganese salts. For example, a therapeutically effectiveamount of a composition comprising one or more manganese salts, is apredetermined amount calculated to achieve the desired effect, i.e., toeffectively promote elastin production, collagen production, cellproliferation, or improved appearance, or improved tissue elasticity inan individual to whom the composition is administered. The tissue inneed of such therapeutic treatment may present lines or wrinkles, sundamaged tissue, or scar tissue.

The term “tissue” refers to any aggregation of similarly specializedcells which are united in the performance of a particular function. Asused herein, “tissue”, unless otherwise indicated, refers to tissuewhich includes elastin as part of its necessary structure and/orfunction. For example, connective tissue which is made up of, amongother things, collagen fibrils and elastin fibrils satisfies thedefinition of “tissue” as used herein. Thus, “tissue” thus includes, butis not limited to skin fibroblasts and smooth muscle cells includinghuman aortic smooth muscle cells. Additionally, elastin appears to beinvolved in the proper function of blood vessels, veins, and arteries intheir inherent visco-elasticity.

The term “unit dose” when used in reference to a therapeutic compositionof the present invention refers to physically discrete units suitable asunitary dosage for the subject, each unit containing a predeterminedquantity of active material calculated to produce the desiredtherapeutic effect in association with the required diluent; i.e.,excipient, carrier, or vehicle.

Embodiments of the present invention relate to compositions comprisingone or more minerals. Such minerals may include divalent manganese basedcompounds, trivalent iron based compounds or salts thereof.

One embodiment of the present invention relates to compositions ofdivalent manganese, trivalent iron, salts thereof or combinationsthereof which improves the appearance, the elasticity, and/or theelastin content of mammalian tissue. The compositions containingdivalent manganese, trivalent iron or salts thereof of the presentinvention induce the synthesis of elastin and collagen in cell cultures.Additionally, the compositions induce elastogenesis in cells derivedfrom subjects of different ages.

One embodiment of the present invention relates to therapeuticcompositions comprising divalent manganese or one or more salts thereof.Suitable manganese salts include, but are not limited to, manganeseascorbate, manganese chloride, manganese gluconate, manganese nitrate,and manganese-PCA, manganese sulfate. Manganese-PCA (“Mn-PCA”) is themanganese salt of L-Pyrrolidone Carboxylic Acid (“L-PCA”).

Manganese is involved in many biochemical processes in the body. It actsas an activator of enzymes involved in proper synthesis of severalhormones including thyroxin in the thyroid gland. It is involved in thesynthesis of numerous proteoglycans, the normal building and function ofcartilages and bones, and the normal development and functions ofcardiovascular system. Manganese is also linked to normal development ofthe brain and maintaining of its psychomotor functions. It is requiredfor normal synthesis melanin, fatty acids and urea. Manganese shows astrong antioxidant activity (by neutralizing superoxide anion viaactivation of manganese superoxide dismutase, Mn-SOD). It is used totreat oxidative skin injury and fibrosis after exposure to UV.

L-Pyrrolidone Carboxylic Acid (“L-PAC”), is a naturally occurringmolecule present in the skin; is a link to energy metabolism (Krebscycle); is involved in the protein pool as a precursor of proline andhydroxyproline; and is involved in skin hydration. PCA is listed amongthe major constituents of the skin's natural moisturizing factor (NMF),which also includes serine, glycine, arginine, ornithine, citrulline,alanine, histidine, and urocanic acid. Sodium-PCA, the sodium salt ofpyrrolidone carboxylic acid, is a major component in skin care productsincluding cleansers and moisturizers. L-PAC is known to enhance theassimilation and the fixation of mineral or organic ions used underpyrrolidone carboxylate form. L-PAC is obtained by the cyclization ofthe L-glutamic acid, amino acid from vegetal origin.

Several references describe the use of manganese as an optionalingredient of a chemical composition related to the treatment of theskin. For example, U.S. Pat. No. 6,255,295 describes preferred forms ofmanganese in such compositions as a manganese salt, such as manganeseascorbate, because the ascorbate is a soluble form of manganese whichfurther provides ascorbic acid, a substance needed for collagensynthesis. This reference describes other manganese salts such, as forexample, sulfate or gluconate, that may be optionally used.

As another example, U.S. Pat. No. 6,645,948 describes a nutritionalcomposition for the treatment of connective tissue in mammals anddescribes manganese as an optional chemical ingredient. This referenceteaches that manganese ascorbate is preferred as this optional chemicalagent because it provides ascorbic acid for collagen synthesis.

Compositions comprising L-pyrrolidone carboxylic acid, pyrrolidonecarboxylic acid, or L-2-pyrrolidone-5-carboxylic acid are typically usedin skin cleansing and moisturizing compositions. For example, U.S. Pat.No. 6,333,039 describes a sanitizing composition that optionallyincludes the use of a moisturizer, of which pyrrolidone carboxylic acidis suitable. A moisturizer is typically a non-occlusive hygroscopicsubstance which retains water and make this water available to the skin.This reference describes examples of such moisturizers as includingglycerin, water-soluble such as sorbitol, hydrolyzed proteins, urea,hydrolyzed starch, hydroxy acids such as lactic acid and fruit acids andsalt derivatives thereof, pyrrolidone carboxylic acid, aloe vera gel,cucumber juice, mineral oils, squalene, and tocophenol. This referencealso states a suitable concentration of this moisturizer in thesanitizing composition of the invention. Preferably, these moisturizingagents, if used, are used in amounts for softening or moisturizing theskin, those amounts typically ranging from 0.1 to about 2 percent byweight.

One embodiment of the present invention relates to compositions oftrivalent iron or trivalent iron based compounds which improve theappearance, the elasticity, and/or the elastin content of mammaliantissue. The compositions containing such trivalent iron based compoundsof the present invention induce the synthesis of elastin and collagen incell cultures. Additionally, the compositions induce elastogenesis incells derived from subjects of different ages.

One embodiment of the present invention relates to therapeuticcompositions comprising trivalent iron or trivalent iron basedcompounds. Suitable iron based compounds include, but are not limitedto, ferric ammounium citrate and ferric chloride.

In one embodiment of the present invention, the compositions may furthercomprise an elastic tissue digest. The term “elastic tissue digest” asused herein refers to any insoluble elastin derived from mammaliantissue or any previously solubilized elastin that is proteolyticallydigested with a protein digesting composition (either chemically orenzymatically). An elastic tissue digest comprises fragments of elastin,microfibrellal proteins, and bioactive peptides associated with elasticfibers. A preferred elastic tissue digest is described in the U.S.Provisional Application Ser. No. 60/447,461 filed Feb 13, 2003 andcorresponding U.S. application Ser. No. 10/778,253 entitled “ElastinDigest Compositions and Methods Utilizing the Same” filed Feb 13, 2004,herein incorporated by a reference in their entireties. The elastictissue digests of the present invention may be obtained from proteolyticdigestion, with a protein digesting composition, of insoluble elastinderived from mammalian ligaments, bovine neck ligaments in particular.The protein digesting composition, for example, may comprise humanelastase enzyme or Proteinase K enzyme. The elastin digest which havebeen identified as being useful in the present invention comprise atleast one amino acid sequence listed in Table 1. Preferably about 25% ofthe elastin digest's sequences is represented by the sequences listed inTable 1.

TABLE 1 Position SEQ ID Cleavage NO. Peptide Site Mol. Wt. Name  1.GAAPG Glycine-Alanine-Alanine-Proline-Glycine  2. GVVPGGlycine-Valine-Valine-Proline-Glycine  3. GGGPGGlycine-Glycine-Glycine-Proline-Glycine  4. GLLPGGlycine-Leucine-Leucine-Proline-Glycine  5. GIIPGGlycine-Isoleucine-Isoleucine-Proline- Glycine  6. GSSPGGlycine-Serine-Serine-Proline-Glycine  7. GTTPGGlycine-Threonine-Threonine-Glycine  8. GCCPGGlycine-Cysteine-Cysteine-Proline-Glycine  9. GMMPGGlycine-Methionine-Methionine-Proline- Glycine 10. GFFPGGlycine-Phenylalanine-Phenylalanine- Proline-Glycine 11. GYYPGGlycine-Tyrosine-Tyrosine-Proline-Glycine 12. GWWPGGlycine-Tryptophan-Tryptophan-Proline- Glycine 13. GDDPGGlycine-Aspartic Acid-Aspartic Acid- Proline-Glycine 14. GNNPGGlycine-Asparagine-Asparagine-Proline- Glycine 15. GEEPGGlycine-Glutamic Acid-Glutamic Acid- Proline-Glycine 16. GQQPGGlycine-Glutamine-Glutamine-Proline Glycine 17. GRRPGGlycine-Arginine-Arginine-Proline-Glycine 18. GHHPGGlycine-Histidine-Histidine-Proline-Glycine 19. GKKPGGlycine-Lysine-Lysine-Proline-Glycine 20. GPPPGGlycine-Proline-Proline-Proline-Glycine 21. G3Hyp3HypPGGlycine-3-hydroxyproline-3- hydroxyproline-Proline-Glycine 22.G4Hyp4HypPG Glycine-4-hydroxyproline-4- hydroxyproline-Proline-Glycine23. RRPEV 13 655.377 Arginine-Arginine-Proline-Glutaraic Acid- Valine24. QPSQPGGV 29 768.377 Glutamine-Proline-Serine-Glutamine-Proline-Glycine-Glycine-Valine 25. PGGV 37 328.175Proline-Glycine-Glycine-Valine 26. GPGV 60 329.175Glycine-Proline-Glycine-Valine 27. KPGV 67 399.248Lysine-Proline-Glycine-Valine 28. GPGL 75 342.190Glycine-Proline-Glycine-Leucine 29. EGSA 81 362.144 GlutamicAcid-Glycine-Serine-Alanine 30. PGGF 90 76.175Proline-Glycine-Glycine-Phenylalanine 31. GGGA 97 260.112Glycine-Glycine-Glycine-Alanine 32. KPGKV 150 527.343Lysine-Proline-Glycine-Lysine-Valine 33. PGGV 163 328.175Praline-Glycine-Glycine-Valine 34. KPKA 90 442.29Lysine-Proline-Lysine-Alanine 35. GPGGV 246 385.196Glycine-Proline-Glycine-Glycine-Valine 36. GPQA 265 371.180Glycine-Proline-Glutamine-Alanine 37. GGPGI 294 39S.212Glycine-Glycine-Proline-Glycine-Isoleucine 38. PGPGA 597 397.196Proline-Glycine-Proline-Glycine-Alanine 39. GPGGV 615 385.196Glycine-Proline-Glycine-Glycine-Valine 40. GQPF 704 447.212Glycine-Glutaitdne-Proline-Phenylalanine 41. GGKPPKPF 723 826.470Glycine-Glycine-Lysine-Proline-Proline- Lysine-Proline-Phenylalanine 42.GGQQPGL 213 655.329 Glycine-Glycine-Glutamine-Glutamine-Proline-Glycine-Leucine 43. MRSL 4 505.268Methionine-Arginine-Serine-Leucine 44. GGPGI 294 399.212Glycine-Glycine-Proline-Gylcine-Isoleucine

Refer to Table 1. A UV chromatogram of Elastin E91 and the location ofexperimentally determined peptide sequences on bovine tropoelastinsequence was conducted. Elastin E91 is a suitable elastin digest of thepresent invention. The GXXPG (SEQ ID NO: 54) sequence accounts for about25% of the total peptide sequence constituting the elastin digest.Without wishing to be bound by theory, it seems the peptides containingthe sequences PGGVLPG (SEQ ID NO: 46), VGVVPG (SEQ ID NO: 47), andIGLGPGGV (SEQ ID NO: 48) are effective in permeating the stratum corneumof the skin. Table 1 offers a list of sequences that constitute about25% of an elastin digest. Additionally, the repeat hexapeptide intropoelastin, VGVAPG (SEQ ID NO: 45), has been identified as a chiefligand for high affinity binding to the cell surface receptor. It hasbeen later established that diverse peptides maintaining a GXXPG (SEQ IDNO: 54) sequence (wherein X is any of the 20 natural amino acids),including the LGTIPG (SEQ ID NO: 49) sequence present on the domain V ofB1 chain of laminin, can also bind to the EBP and induce similarcellular effects (U.S. Application Ser. No. 10/778,253 entitled “ElastinDigest Compositions and Methods Utilizing the Same” filed Feb 13, 2004).

Fibrous protein tissue comprising elastin or collagen-like tertiarystructures and tropoelastin are examples of proteins and peptides whichmay be digested to produce an elastic tissue digest suitable incompositions of the present invention. Protein, peptides, elastin ortropoelastin may be obtained from various animal tissues. A source ofprotein for the elastin is animal tissue. The elastic ligamentsprominent in the necks of grazing animals, such as cows, horses, pigsand sheep, are especially rich in elastin; preferably the protein sourceis insoluble bovine elastin. Elastin may be obtained from these tissuesby mild hydrolysis of elastin from the neck tendons of young animals,which have first been cleaned, defatted and pulverized. Elastin suitablefor use in the present invention can be prepared by the methods andmaterials, for example, from bovine nuchal ligament, fibrinogen andthrombin as described and incorporated herein by reference in U.S. Pat.No. 5,223,420. Elastin may also be obtained from digestion of elastincomprising tissues including arteries (e.g., coronary or femoralarteries, for example, from swine), umbilical cords, intestines,ureters, skin, lungs, etc. from such grazing animals. Any method ofremoving cellular material, proteins and fats from the native matrixwhile leaving the extracellular elastin matrix intact can be used. Thesemethods can involve a combination of acidic, basic, saline, detergent,enzymatic, thermal or erosive means, as well as the use of organicsolvents such as chloroform and methanol. This may include-incubation insolutions of sodium hydroxide, formic-acid, trypsin, guanidine, ethanol,diethylether, -acetone, t-butanol, and sonication.

Suitable sources of elastin include hydrolyzed elastin peptides. Forexample, commercially available, Elastin E91 preparation from ProteinPreparations, Inc., St. Louis, Mo., having a molecular weight of about1,000 to 60,000 dalton may be digested with human elastase to form anelastic tissue digest suitable in the present invention. Additionally, aseries of digests available under the trade name (Pro K) are suitableelastic tissue digests and are derived from the proteolytic digestion ofinsoluble elastin derived from bovine neck ligaments, commerciallyavailable from Human Matrix Sciences, LLC. ProK formulations includeProK-60 and ProK-60P, wherein “ProK” refers to the proteinase K enzymeused to digest insoluble bovine elastin, “60” refers to the temperatureof digestion and “P” refers to the presence of a chemical preservativein the elastic tissue digest, such as cetylpyridinium chloride and orother chemical preservatives. Elastic tissue digests prepared byproteolytic digestion comprise a mixture of peptides, cytokines,epitopes, and growth factors.

The compositions of the present invention may also include connectivetissue derived additives, including, but not limited to connectivetissue proteins, collagens, proteoglycans, and glycoproteins frommammals and non-mammals, including but not limited to fish.

The compositions of the present invention improve facial lines andwrinkles through induction of new connective tissues synthesis in skin.The compositions are used for the restoration of cutaneous connectivetissue proteins in the skin. The present invention relates totherapeutic skin care products based on biologically active compositionscomprising one or more manganese salts.

In one embodiment of the present invention, compositions may beformulated into a cosmetic skin care product to aid or facilitate theassembly of new elastic fibers in skin. Other suitable formulationsinclude fibroblast injections for the clinical treatment for theimprovement of facial lines and wrinkles through cell culture of patientdermal fibroblasts and re-introduction via injection into sitespresenting visible lines and wrinkles.

Extracellular matrix components include fibrillin I, a major componentof microfibrillen scaffold of elastic fibers, collagen type I, II, andIII, fibronectin chondroiton sulfate-containing glycosaminoglycans,elastin, and lysyl oxidase. Composition and method embodiments of thepresent invention may stimulate the synthesis one or more of theextracellular matrix components within fibroblasts. Additionally,composition and method embodiments of the present invention maystimulate cell proliferation and elastin production in smooth musclecells.

Human Aortic Smooth Muscle Cells (HAOSMC) are derived from tunica intimaand tunica media of normal human, fibrous plaque-free aorta. Arterialsmooth muscle cells are capable of synthesizing collagen, elastin,myosin and glycosaminoglycan. Increased production of connective tissuecomponents, hyperplasia and hypertrophy of intimal smooth muscle cellsare found to gradually occlude the vessel lumen in atherosclerosis.HAOSMC respond to various factors by proliferating or differentiating.HAOSMC provides a well established cell system for the study of humanvascular disorders such as atherosclerosis and stroke.

Another embodiment of the present invention is a method for clinicallytreating facial lines and wrinkles of a patient comprising providing acomposition comprising one or more divalent manganese or divalentmanganese based compounds. The composition provided to a site presentingvisible lines and wrinkles may comprise manganese-PCA or manganesechloride. The compositions comprising manganese salts may furthercomprise an elastic tissue digest. The compositions comprising manganesesalts may further comprise retinoic acid, excipients, or otheradditives.

Another embodiment of the present invention is a method for clinicallytreating facial lines and wrinkles of a patient comprising providing acomposition comprising trivalent iron or trivalent iron based compounds.The composition provided to a site presenting visible lines and wrinklesmay comprise ferric ammonium citrate or ferric chloride. Thecompositions comprising iron or iron based compounds may furthercomprise an elastic tissue digest. The compositions may further compriseretinoic acid, excipients, or other additives.

Since cutaneous aging is associated with a marked decrease in number offibroblasts and gradual thinning and disappearance of elastic fibers inentire dermis, one embodiment of the present invention is the selectionof the most active preparation of compositions comprising one or moremanganese salts that would rejuvenate human skin, by stimulation offibroblasts proliferation and migration, as well as induction of theirability to synthesize a new elastin-enriched matrix.

Embodiments of the compositions may be cosmetic, pharmacological, ortherapeutic and are useful for treating mammalian tissue. Compositionscomprising one or more of divalent manganese based compounds, trivalentiron based compounds or salts thereof may optionally comprise otherepitopes for extracellular matrix proteins, cytokines, and growthfactors. These additional components may include tropoelastin, thepeptide VGVAPG (SEQ ID NO: 45), desmosine, tropoelastin-Exon 36,fibrillin 1, MAGP 1, LT BP 2, versican, collagen type I, collagen typeIV, fibronectin, EBP, PDGF, βFGF, αFGF, and IL-1 β.

Embodiments of the compositions may be cosmetic, pharmacological, ortherapeutic and are useful for treating mammalian tissue. Compositionscomprising one or more of divalent manganese based compounds, trivalentiron based compounds or salts thereof may optionally comprise otherepitopes for extracellular matrix proteins, cytokines, and growthfactors. These additional components may include tropoelastin, thepeptide VGVAPG, desmosine, tropoelastin-Exon 36, fibrillin 1, MAGP 1, LTBP 2, versican, collagen type I, collagen type IV, fibronectin, EBP,PDGF, βFGF, αFGF, and IL-1β.

Additional components of the therapeutic compositions include anysuitable additive that has been used in cosmetics or other skin carecompositions. These include, but are not limited to aloe vera,antioxidants, azulene, beeswax, benzoic acid, beta-carotene, butylstearate, camphor, castor oil, chamomile, cinnamate, clay, cocoa butter,coconut oil, cucumber, dihydroxyacetone (DHA), elastin, estrogen,ginseng, glutamic acid, glycerin, glycolic acid, humectant,hydroquinone, lanolin, lemon, liposomes, mineral oil, monobenzone,nucleic acids, oatmeal, paba, panthenol, petroleum jelly, propeleneglycol, royal jelly, seaweed, silica, sodium lauryl sulfate sulfur,witch hazel, zinc, zinc oxide, copper, hyaluronic acid and shea butter.Additionally, compounds comprising sodium are suitable additives fortherapeutic compositions of the present invention. Sodium has beenlinked to stimulate elastogenesis. Compounds comprising copper areanother suitable additives in the therapeutic compositions of thepresent invention.

The compositions comprising divalent manganese based compounds ortrivalent iron based compounds may further comprise retinoic acid,excipients, or other additives. Retinoic acid acts to stimulate collagenproduction.

Additives which aid in improving the elasticity of elastin comprisingtissues such as tretinoin, vitamin E, sources of copper, and/ormagnesium ions, retinol, copper peptides, and any one of the 20 standardamino acids may also be added to the compositions of the presentinvention. Additives which induce deposition of tropoelastin onmicrofibril scaffolds, and compounds which induce lysyl oxidaseactivity, such as transforming growth factor beta-1 and copper, may alsobe added to such compositions. Compositions of the present invention mayinclude a therapeutically and biologically compatible excipient.

Another embodiment of the present invention is a method of treating anelastin comprising tissue, the method comprising administering to a sitein need thereof on a mammal an effective amount of a compositioncomprising one or more divalent manganese or salts thereof, forimproving the elasticity of said tissue. One such method ofadministration is injection. The composition injected into a sitepresenting visible lines and wrinkles may comprise manganese-PCA ormanganese chloride. The compositions comprising the divalent manganesemay further comprise an elastin digest. The compositions comprisingdivalent manganese may further comprise retinoic acid, excipients, orother additives. Other additives include hyaluronic acid.

Another embodiment of the present invention is a method of treating anelastin comprising tissue, the method comprising administering to a sitein need thereof on a mammal an effective amount of a compositioncomprising a trivalent iron based compound or mixtures thereof, forimproving the elasticity of said tissue. One such method ofadministration is injection. The composition injected into a sitepresenting visible lines and wrinkles may comprise ferric ammoniumcitrate or ferric chloride. The compositions may further comprise anelastin digest, retinoic acid, excipients, hyaluronic acid or otheradditives.

The preparation of a pharmacological composition that contains activeingredients dispersed therein is well understood in the art. Typicallysuch compositions if desired, may be prepared as sterile compositionseither as liquid solutions or suspensions, aqueous or non-aqueous,however, suspensions in liquid prior to use can also be prepared.

The active ingredient of the present composition embodiments may bemixed with excipients which are pharmaceutically acceptable andcompatible with the active ingredient and in amounts suitable for use inthe therapeutic methods described herein. Various excipients may be usedas carriers for the peptide compositions of the present invention aswould be known to those skilled in the art. For example, the divalentmanganese based compounds and trivalent based compounds may be dissolvedin excipients such as water comprising solutions, alcohol comprisingmixtures, intravenous and saline comprising mixture, dextrose, glycerol,ethanol or the like and combinations thereof. In addition, if desired,the composition can contain minor amounts of auxiliary substances suchas wetting or emulsifying agents, pH buffering agents and the like whichenhance the effectiveness of the active ingredient. Formulationscomprising one or more divalent manganese, trivalent iron or saltsthereof may be prepared by mixing such excipients with the activeingredient.

The divalent manganese or divalent manganese based compounds in theformulation comprise from about 0.0002% to about 90% by weight of theformulation. These formulations may be employed directly as aconstituent of therapeutic or cosmetic treatments, such as emulsions,lotions, sprays, ointments, creams and foam masks. Final products maycontain up to 10% by weight but preferably 0.001 to 5% of such activeingredient though of course more concentrated or more dilute solutionsmay also be used in greater or lesser amounts. For example, an eye creammay comprise about 0.0012% (w/w) and a facial cream may comprise about0.0003% (w/w) of a divalent manganese in an excipient. Specifically, theone or more divalent manganese based compounds of the present inventionexists in cosmetic or therapeutic compositions at concentrations ofabout 0.5-25 μM, preferably about 5-25 μM.

The trivalent iron, trivalent iron based compounds or salts thereof inthe formulation exist in cosmetic or therapeutic compositions atconcentrations of about 5-75 μM, more preferably about 5-50 μM.

Physiologically tolerable carriers and excipients are well known in theart. Other equivalent terms include physiologically acceptable or tissuecompatible. Exemplary of liquid carriers are sterile aqueous solutionsthat contain no materials in addition to the active ingredients andwater, or contain a buffer such as sodium phosphate at physiological pHvalue, physiological saline or both, such as phosphate-buffered saline.Still further, aqueous carriers can contain more than one buffer salt,as well as salts such as sodium and potassium chlorides, dextrose,propylene glycol, polyethylene glycol and other solutes.

In one embodiment of the present, a composition comprising one or moredivalent manganese or divalent manganese based compounds may beformulated into gels, creams and lotions. Liquid compositions can alsocontain liquid phases in addition to and to the exclusion of water.Exemplary of such additional liquid phases are glycerin, vegetable oilssuch as cottonseed oil, organic esters such as ethyl oleate, andwater-oil emulsions. In such compositions the peptides are wet by theliquid or they may be soluble in the liquid. Compositions may be mixedwith gels, creams, or ointments and may include but are not limited topetroleum jelly and coco butter. In these mixtures the compositions maybe in the form of a suspension or form a gel with the excipient. Thedivalent manganese compounds may also be mixed with solids such asstarches and methyl cellulose.

A therapeutically effective amount of a composition comprising divalentmanganese or divalent manganese based compounds is a predeterminedamount calculated to achieve the desired effect, i.e., to effectivelypromote improved tissue elasticity or the appearance of skin. Inaddition, an effective amount can be measured by improvements in one ormore symptoms occurring in a mammal. A therapeutically effective amountof a composition comprising one or more manganese salts of thisinvention is typically an amount such that when it is administered in aphysiologically tolerable excipient composition, it is sufficient toachieve an effective local concentration in the tissue. Effectiveamounts of compounds of the present invention may be measured byimprovements in tissue elasticity, endogenous elastin production, tissuefunction (elasticity), or tissue appearance and tone.

In one embodiment of the present, a composition comprising one or moretrivalent iron or trivalent iron based compounds may be formulated intogels, creams and lotions. Liquid compositions can also contain liquidphases in addition to and to the exclusion of water. Exemplary of suchadditional liquid phases are glycerin, vegetable oils such as cottonseedoil, organic esters such as ethyl oleate, and water-oil emulsions. Insuch compositions the peptides are wet by the liquid or they may besoluble in the liquid. Compositions may be mixed with gels, creams, orointments and may include but are not limited to petroleum jelly andcoco butter. In these mixtures the compositions may be in the form of asuspension or form a gel with the excipient. The iron based compoundsmay also be mixed with solids such as starches and methyl cellulose.

A therapeutically effective amount of a composition comprising one ormore trivalent iron or trivalent iron based compounds is a predeterminedamount calculated to achieve the desired effect, i.e., to effectivelypromote improved tissue elasticity or the appearance of skin. Inaddition, an effective amount can be measured by improvements in one ormore symptoms occurring in a mammal. A therapeutically effective amountof a composition is typically an amount such that when it isadministered in a physiologically tolerable excipient composition, it issufficient to achieve an effective local concentration in the tissue.Effective amounts of compounds of the present invention may be measuredby improvements in tissue elasticity, endogenous elastin production,tissue function (elasticity), or tissue appearance and tone. In apreferred embodiment, a therapeutically effective amount of an ironbased compound is from about 5 to about 75 μM, or more, preferably about5 to 50 μM.

Thus, the dosage ranges for the administration of a peptide of theinvention are those large enough to produce the desired effect in whichthe condition to be treated is ameliorated. The dosage should not be solarge as to cause adverse side effects. Generally, the dosage will varywith the age, condition, and sex of the patient, and the extent of thedisease in the patient, and can be determined by one of skill in theart. The dosage can be adjusted in the event of any complication.

Another embodiment of the present invention as a method of treatingconnective tissue, wherein an effective amount of a compositioncomprising divalent manganese or divalent manganese based compounds isadministered. The composition is administered to a site in need thereof,for the improvement of the elasticity of the tissue.

Suitable applications of the present invention include therapeuticcompositions comprising one or more of divalent manganese, divalentmanganese, trivalent iron and trivalent iron based compounds for use inoral applications, such as compositions to be applied to gums and otherconnective tissue and ligaments in the mouth. For example, compositionsmay be incorporated into toothpastes or mouthwashes in order to providea therapeutic composition for rebuilding connective tissue in the mouth.Additionally, other periodontal and orthodontic applications arepossible, such as providing a therapeutic composition comprising anelastin digest to the gums of patients who wear braces or otherorthodontic devices in order to heal minor ulcerations that result onthe gums or mouth tissue from the devices.

Another embodiment of the present invention is a therapeutic compositioncomprising one or more of divalent manganese, divalent manganese,trivalent iron and trivalent iron based compounds to be used tostrengthen elastic fibers around follicles, in order to prevent hairloss. Strengthening follicles containing hair by the use of atherapeutic composition is within the scope of the present invention. Atherapeutic composition may be provided to the site on a patient thatcontains follicles. Elastin production around the follicle will bestimulated, strengthening the follicle and thus prevent hair loss at thesite.

A further application according to another embodiment of the presentinvention is a therapeutic composition comprising one or more ofdivalent manganese, divalent manganese, trivalent iron and trivalentiron based compounds to treat opthalmologic injuries or conditions, suchas a corneal ulceration. A therapeutic composition may be provided to asite which comprises connective tissue. A therapeutic composition may beprovided to a site which exhibits a opthalmologic injury or condition inorder to stimulate the production of elastin and collagen and/or toinduce cellular proliferation of said connective tissue.

Another application for the therapeutic compositions of the presentinvention is the inhibition of hyperproliferative collagenous neointimalformation after angioplasty and stenting of injured arteries. It hasbeen found that therapeutic compositions comprising one or more divalentmanganese or divalent manganese based compounds administered to culturesof arterial smooth muscle cells vigorously stimulate deposition ofinsoluble elastin. However, a net decrease in proliferation of activatedarterial smooth muscle cells in observed in these same cultures overtime. While not wishing to be bound by theory, this net decreaseobserved may be due to the fast sequestration of endogenous andexogenous growth factors by the newly produced elastic tissue. Thus,growth factors (PFGF, EGF, FGF, TGFβ) trapped by the hydrophobic elastinare unable to interact with theirs respective cell surface receptors andstimulate proliferation of activated smooth muscle cells.

Thus, therapeutic compositions of divalent manganese and divalentmanganese based compounds stimulate induction of elastic fibers, providebetter strength and resiliency of the injured artery, and inhibit SMCproliferation, therefore strongly facilitating the proper healing of theinjured arteries treated with stents. Therapeutic compositions ofdivalent manganese and divalent manganese based compounds may alleviatethe undesirable response of SMC to stent-induced irritation, that oftenmaterialize as the detrimental hyper-proliferative collagenous scars,which overgrow the stent meshworks and eventually cause occlusion of thestent-treated arteries. As such, a therapeutic composition comprisingone or more divalent manganese or divalent manganese based compounds issuitable for treating arteries in a number of capacities.

In a further embodiment, the divalent manganese or trivalent iron basedcompounds of the present invention may be useful for intradermalthickening. In a preferred embodiment, the compounds are formulated tobe administered via intradermal injections to sites in need of dermalfilling or thickening.

In a further embodiment, a method of healing wounds is provided. In oneembodiment, compositions containing divalent manganese based compounds,trivalent iron based compounds, salts or combinations thereof areadministered to a wound to increase connective tissue formation. In oneembodiment, the compositions are formulated for transdermal application.

In another embodiment a composition comprising desferrioxamine isprovided. The desferrioxamine containing composition may be useful intreating skin damage in patients with iron overload. In a furtherembodiment, the composition comprises about 50 to about 75 μM ofdesferrioxamine.

A method of stimulating the endogenous synthesis and deposition ofelastin comprising administering to a site in need thereof on a mammalan effective amount of a therapeutic composition comprising a trivalentiron based compound or manganese based compound is provided.

In a further embodiment, A method of regulating elastin messagestability comprising administering to a site in need thereof on a mammalan effective amount of a therapeutic composition comprising a trivalentiron based compound.

In another embodiment, a method of regulating reactive oxygen specieswithin connective tissue comprising administering to a site in needthereof on a mammal an effective amount of a therapeutic compositioncomprising a bivalent manganese based compound or trivalent iron basedcompound is provided. In a further embodiment the composition mayfurther comprise an intracellular hydroxyl radical scavenger.

Embodiments of the present invention may involve local administration ofa pharmacologically active composition comprising one or more ofdivalent manganese, divalent manganese, trivalent iron and trivalentiron based compounds to a tissue site on a mammal, and therefore is bestexpressed in unit dosage form. Such local administration is typically bytopical or local administration of a liquid or gel composition. Thus atherapeutic composition can be administered via a solid, semi-solid(gel) or liquid composition, each providing particular advantages forthe route of administration.

A composition of the present invention, including optionally an elastinpeptide digest of the invention, can be administered parenterally byinjection or by gradual infusion over time. For example, elastin peptidedigest of the invention can be administered topically, locally, perilesionally, perineuronally, intracranially, intravenously,intrathecally, intramuscularly, subcutaneously, intracavity,transdermally, dermally, or via an implanted device, and they may alsobe delivered by peristaltic means. Although local topical delivery isdesirable, there are other means of delivery, for example: oral,parenteral, aerosol, intramuscular, subcutaneous, transcutaneous,intamedullary, intrathecal, intraventricular, intravenous,intraperitoneal, or intranasal administration. The diffusion of thecomposition into the tissue may be facilitated by application ofexternal heat or soaking of skin in a heated solution comprising aneffective amount of the composition. Heating of a site on a patientcomprising tissue is known to open pores, activate the variousmechanisms of a cell, and increase diffusion into said tissue and cells.Heating in connection with providing a therapeutic composition to a sitecomprising connective tissue is therefore a preferred embodiment of thepresent invention.

Regardless of the method of administration of the composition, one ormore components of the composition penetrate the tissue to which it isapplied. Penetration for purposes of this invention is used equivalentlywith diffusion or permeation of the one or more components of thecomposition into the tissue to effect a desired therapeutic effect.

In one embodiment, the compositions and products of the presentinvention may be administered with heat. The application of heat mayoccur before, after or essentially simultaneous with application oradministration of the composition or product.

In one embodiment of the present invention, compositions may beadministered as a pharmaceutical composition in the form of a solution,gel or suspension. However, therapeutic compositions of the presentinvention may also be formulated for therapeutic administration as atablet, pill, capsule, aerosol, liposomes, sustained releaseformulation, or powder.

It is further contemplated that the compositions of the presentinvention as described herein can be used therapeutically in a varietyof applications. For example, as described above, a variety of usefulcompositions and formats, including bioabsorbable materials or matricesmay be used in conjunction with the compositions of the presentinvention to treat tissues requiring elastin.

The various embodiments of the present invention may be used to improvethe elasticity, cell proliferation, endogenous elastin production,function, and/or appearance of properties of tissues. Compositions ofthe invention may be applied to tissue in a therapeutically effectiveamount for the treatment of various diseases. Such a composition maystimulate native tropoelastin production within the cell, may result incell proliferation, and may also provide a secondary source of peptidesegments from elastin for cross linking in the extracellular matrix ofcells to which it is applied.

The compositions induce synthesis and deposition of elastin and inducecellular proliferation in normal human dermal fibroblasts and humanaortic smooth muscle cells across various ages. The following effects inculture compositions are better understood in reference to the examplesbelow. Examples of compositions and method of making compositions of thepresent invention are shown by the non-limiting examples below.

EXAMPLE 1

Materials and Methods. The following materials and methods apply toExamples 1-6 herein. Manganese-PCA (Mn-PCA) from DD Chemco, IrvineCalif. was used in the following Examples 1-6. The ProK formulations areelastin peptide digests available from Human Matrix Science, LLC.Biological effects of the preparations of the following Examples weretested in cultures of skin fibroblasts derived from healthy caucasianfemales of different ages: Females of the ages of 50 years old (code2-4), 26 years old (code 9063) and 3 years old (code 4184) were used.All of these fibroblasts were originally isolated by digestion of skinbiopsies with mixture of 0.25% collagenase type I (Sigma) and 0.05%DNAse type 1 (Sigma) and then passaged by trypsinization and maintainedin alpha-minimum essential medium supplemented with 20 mM Hepes, 1%antibiotics/antimycotics, 1% L-Glutamate and 5% fetal bovine serum(FBS). In all experiments of Examples 1-6, the consecutive passages 3-7were tested. In some experiments the serum free medium was also used.

Smooth muscle cells were isolated in the following manner porcinethoracic aortas and coronary arteries were dissected from young pigsobtained from local slaughterhouse. Passage two of human aortic smoothmuscle cells from a normal subject was purchased from Clonetics Inc.(San Diego, Calif.). Arterial tissues were diced and explanted in a-MEM(modified Eagle's medium) supplemented with 10% FBS, 25 mM HEPES,L-glutamine, and antibodies. Tissue samples were diced and cellsisolated by collagenase and elastase digestion as previously described.

The above prepared fibroblasts and smooth muscle cells were cultured inthe presence or absence of (0.5-5 μM) of a manganese salt. Deposition ofextracellular matrix components, elastin and collagen type I wasassessed in 5-10 days old cultures by immunohistochemistry with a panelof specific antibodies. Production of insoluble elastin, the majorcomponent of elastic fibers, was assessed biochemically after metaboliclabeling of cultured fibroblasts with [³H]-valine. Levels of elastinmRNA were assessed by Northern Blot Analysis. Cellular proliferationrates of fibroblasts and smooth muscle cells cultured in the presenceand absence of manganese salt compositions was assessed by incorporationof [³H]-thymidine and by assay of total DNA.

Refer to FIG. 1, which illustrates both the elastic fibers detected byimmunocytochemistry and the morphometric analysis of elastic fibers.MnCl₂ and Mn-PCA were introduced into the fibroblasts derived from thevarious aged subjects over various concentrations. Both MnCl₂ and Mn-PCAwere shown to induce synthesis of elastin in human dermal fibroblastcultures, across all concentrations, 0.5 μM-2.0 μM. Thus the depositionof extracellular matrix components, elastin and collagen type I wasinduced by both MnCl₂ and Mn-PCA compositions.

EXAMPLE 2

Mn-PCA in combination with ProK-60 and ProK-60P. Refer to FIG. 2, whichillustrates the deposition of insoluble elastin in human skinfibroblasts from the 3 year old female and the 50 year old female. Aftermetabolic labeling with [³H]-valine, the newly synthesized insolubleelastin in fibroblast cultures stimulated with Mn-PCA andMn-PCA/ProK-60, Mn-PCA/ProK-60P combinations showed increased depositionof cross-linked elastin (insoluble elastin). The fibroblasts from the 3year old and 50 year old subjects were tested.

EXAMPLE 3

Mn-PCA in combination with Retinoic Acid. Immunohistochemical analysisof collagen type I in human dermal fibroblast cultures stimulated withMn-PCA and Mn-PCA/Retinoic Acid combination revealed an increaseddeposition in collagen type I. Refer to FIG. 3, which illustrates theimmunohistochemical analysis of collagen type I levels in human dermalfibroblasts. By comparison to the control it is seen that collagenproduction was stimulated by Mn-CPA alone and Mn-CPA in combination withretinoic acid.

EXAMPLE 4

Manganese compositions induce cellular proliferation. FIG. 4 showsinduced cellular proliferation rates in human dermal fibroblasts in the26 year old female. Referring to FIG. 4, Mn-PCA was shown to stimulatedermal fibroblast proliferation by itself and in combination withProK-60 and ProK-60P as confirmed by both total DNA content and[³H]-thymidine incorporation assays.

EXAMPLE 5

Induced extracellular matrix synthesis and mitogenic response of humansmooth muscle cells with various manganese salts was observed. Referringto FIG. 5, a Northern Blot analysis of human smooth muscle cells withvarious manganese salts, including Mn-PCA, manganese chloride andmanganese sulfate. Northern blot analysis of elastin mRNA levels inhuman aortic smooth muscle cells demonstrates that the various manganesesalts can induce transcription of the elastin gene. Specifically, asseen in FIG. 5, Mn-PCA induced nearly 66% more elastin transcriptionover the control. As seen in FIG. 5, comparison to the control revealsthe effectiveness of manganese salt compositions in inducing cellproliferation.

Porcine thoracic aortas and coronary arteries were dissected from youngpigs obtained from local slaughterhouse. Passage two of human aorticsmooth muscle cells from a normal subject was purchased from CloneticsInc. (San Diego, Calif.). Arterial tissues were diced and explanted ina-MEM (modified Eagle's medium) supplemented with 10% FBS, 25 mM HEPES,L-glutamine, and antibodies. Tissue samples were diced and cellsisolated by collagenase and elastase digestion as previously described.Cells were maintained in a-MEM supplemented with 5% FBS and wereroutinely passaged by trypsinization. All the experiments were performedusing SMC at passage 2-5. All SMC cultures were found to be positive forindirect immunofluorescent staining with a monoclonal antibody againsthuman von Willebrand factor (Sigma, A2547) and negative for a polyclonalantibody against human von Willebrand factor (Sigma, F3520). Aortic andcoronary artery SMC's were plated at the initial density 50,000 dish,either directly on plastic or on coverslips, and maintained for 1-2 daysuntil confluency. Cultures were then divided into experimental groupsand maintained in the presence and absence of experimental reagents for7 days. Fresh media were added at days 3 and 5.

EXAMPLE 6

Induced elastin synthesis in human in smooth muscle cells with manganesesalts in combination with ProK-60, ProK-60P, and retinoic acid wasobserved. Metabolic labeling of newly synthesized insoluble elastin byhuman aortic smooth muscle cells demonstrated nearly a two-fold increasein elastin synthesis induced by Mn-PCA and nearly a three-fold increasein elastin synthesis induced by a combination of ProK-60P, Mn-PCA andretinoic acid, over the control.

FIG. 6 illustrates the [³H]-valine incorporation assays, the total DNAassays, and the Immunohistochemical labeling of elastic fibers in humanaortic smooth muscle cells, for the various manganese salts incombination with ProK-60, ProK-60P, and retinoic acid. FIG. 6 alsoincludes an assessment by incorporation of [³H]-thymidine whichillustrates the inducement of cellular proliferation by the manganesesalt compositions.

EXAMPLE 7

Materials. All chemical-grade reagents, catalase, desferrioxamine (DFO),dichlorobenzimidazole riboside (DRB), dimethylthiourea (DMTU), ferricammonium citrate (FAC), superoxide dismutase (SOD), tempol were allobtained from Sigma (St. Louis, Mo.), and Dulbecco's modified eagle'smedium (DMEM), fetal bovine serum (FBS), 0.2% trypsine-0.02% EDTA andother cell culture products from GIBCO Life Technologies (Burlington,ON). 5-(and-6)-chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate,acetyl ester (CM-H₂DCFDA) was obtained from Molecular Probes (Eugene,Oreg.). Polyclonal antibody to tropoelastin was purchased from ElastinProducts (Owensville, Mich.).

Secondary antibody fluorescein-conjugated goat anti-rabbit (GAR-FITC)was purchased from Sigma. DNeasy Tissue system for DNA assay and RNeasyMini Kit for isolation of total RNA were purchased from Qiagen(Mississauga, ON). OneStep RT-PCR Kit was purchased from Qiagen(Mississauga, ON). SuperScript First-Strand Synthesis System for RT-PCRwas purchased from Invitrogen Life Technologies (Carlsbad, Calif.).Taqman Universal PCR master mix, Taqman GAPDH control andAssays-on-Demand Gene Expression probe for elastin were purchased fromApplied Biosystems (Foster City, Calif.). The radiolabeled reagents,[³H]-valine, and [³H]-thymidine and Rediprime (II) Random Primerlabeling system were purchased from Amersham Canada Ltd. (Oakville, ON).Hybridization solution Miracle I lyb was purchased from Stratagene(Cedar Creek, Tex.) and the human GAPDH control was purchased fromClontech (Palo Alto, Calif.).

Cultures of Normal Human Skin Fibroblasts. Fibroblasts grown from skinbiopsy explants of six normal subjects, aged from 2 months to 10 years,were obtained from the cell repository at The Hospital for Sick Childrenin Toronto with the permission of the Institutional Ethics Committee.Fibroblasts were routinely passaged by trypsinization and maintained inDulbecco's modified eagle's medium (DMEM) supplemented with 1%antibiotics/antimycotics, and 10% fetal bovine serum (FBS). In alldescribed experiments passage 2-6 were used.

In experiments aimed at assessing ECM production fibroblasts wereinitially plated (100,000 cells/dish) and maintained in normal mediumuntil confluency at which point they produce abundant ECM. Confluentcultures were then treated for 72 hours with or without ferric ammoniumcitrate (FAC) producing iron concentrations from 2-200 μM. The low ironconcentration (2 and 20 μM) of iron utilized in the present studyremained in range that did not induce any disturbances in cellularmetabolism when tested by other investigators. The high ironconcentration (200 μM) was comparable to concentrations used in studiesof iron overload.

In some experiments the membrane permeable ferric iron chelator, DFO,was added 30 minutes prior to FAC treatment. For the experimentsconducted in the presence of various antioxidants, the antioxidants wereapplied one hour prior to FAC treatment. For experiments conducted inserum free conditions, 7 day-old confluent fibroblast cultures werestarved for 12 hours in serum free medium and incubated with variousconcentrations of iron (as FAC) for additional 72 hours in serum freemedium.

Immunostaining. At the end of the incubation period confluent cultureswere fixed in cold 100% methanol at −20° C. for 30 minutes and blockedwith 1% normal goat serum for 1 hour at room temperature. Cultures werethen incubated for 1 hour with 10 μg/ml of polyclonal antibody totropoelastin followed by an hour incubation with fluorescein-conjugatedgoat anti-rabbit (GAR-FITC). Nuclei were counterstained withpropidium-iodide. Secondary antibody alone was used as a control. All ofthe cultures were then mounted in elvanol, and examined with an NikonEclipse E1000 microscope attached to a cooled CCD camera (Qlmaging,Retiga EX) and a computer-generated video analysis system (Image-ProPlus software, Media Cybernetics, Silver Springs, Md.).

Quantitative assays of Tropoelastin and Insoluble Elastin. Normal humanskin fibroblasts were grown to confluency in 35 mm culture dishes(100,000 cells/dish) in quadruplicates. Then, 2 μCi of [³H]-valine/ml offresh media was added to each dish, along with or without 2, 20, 100,200 μM of FAC. Cultures were incubated for 72 hours, and the soluble andinsoluble elastin was assessed separately in each dish. The cells wereextensively washed with PBS and the soluble proteins present in theintracellular compartments were extracted overnight at 4° C. with 0.1 Macetic acid in the presence of proteinase inhibitors. Aftercentrifugation the supernatants were pre-cleaned by 30 minutesincubation with 50 p. 1 of 4% protein A-beaded agarose, then 500 μl ofthe supernatant was incubated with 5 μg of polyclonal antibody totropoelastin for 2 hours and subsequently with 50 μl of 4% proteinA-beaded agarose for 3 hours at 4° C. The protein A-containing beadswere sedimented by centrifugation; washed with immunoprecipitationbuffer, mixed with scintillation fluid and counted. The remainingcultures containing cell remnants and deposited insoluble extracellularmatrix were scraped and boiled in 500 μl of 0.1 N NaOH for 45 minutes tosolubilize all matrix components except elastin. The resulting pelletscontaining the insoluble elastin were then solubilized by boiling in 200μl of 5.7 N HCl for 1 hour, and the aliquots were mixed in scintillationfluid and counted. Aliquots taken from each culture were also used forDNA determination according to (47), using the DNeasy Tissue System fromQiagen. Final results reflecting amounts of metabolically labeledinsoluble elastin in individual cultures were normalized per their DNAcontent and expressed as CPM/1 DNA. In separate experiments, thespecified treatment in figure legends were added along with 2 μCi of[³H]-valine/ml media to normal human skin fibroblasts grown toconfluency in 35 mm culture dishes (100,000 cells/dish) inquadruplicates for 72 hours. The conditioned media was then removed andthe cell layers were washed and incorporation of [³H]-valine into theinsoluble elastin was assessed as described above.

Assessment of Cell Proliferation. Normal human skin fibroblasts weresuspended in DMEM containing 10% FBS and plated in 35 mm culture dishes(100,000 cells/dish) in quadruplicates. Twenty-four hours later, thecells were transferred to the serum-free medium for synchronization oftheir cell cycle and then maintained in the presence or absence of FAC(2-200 μM) and 2 μCi of [³H]-thymidine/ml in media with 10% FBS for 72hours. These cultures were then washed in PBS and treated with cold 5%trichloroacetic acid twice for 10 minutes at 4° C. For 30 minutes, 0.5ml of 0.3 N NaOH was added to all dishes, and 200 μl aliquots of eachculture were mixed with scintillation fluid and counted.

Assays of Intracellular ROS levels. The ROS-sensitive fluorescent probe,CM-H₂DCFDA has been used to detect oxidative activity in culturedfibroblasts. This probe passively diffuses into the cell interior andonly upon oxidation it releases a fluorescent product that can bevisualized under fluorescent microscope or captured by flowcytophotometry, when it is excited at 480 nm. To measure intracellularROS production normal human skin fibroblasts were plated on glasscoverslips in 35 mm dishes (50,000 cells/dish) and grown to confluency.The cells were then washed with PBS and incubated with or without 10 μMof CM-H₂DCFDA for 30 minutes in fresh media. The cells were then washedagain in PBS and incubated with new media in the presence or absence ofFAC (2-400 μM) for 3 additional hours. The cells were then washed twicewith PBS before being mounted to the glass slides and the images werecaptured under a fluorescent microscope under identical parameters ofcontrast and brightness.

In addition, the quantification of this reaction was performed by flowcytometry (λ excitation 480 nm; λ emission 520 nm). Quadruplicatecultures of fibroblasts were preincubated with CM-H₂DCFDA and maintainedin the presence or absence of FAC as described above. In order to reducestress-induced oxidant activation, the cells were cooled and harvestedby trypsinization at 4° C. They were then collected by centrifugation(4° C., 1000 RPM for 3 minutes), washed in cold PBS and fixed with 4%formaldehyde for 10 minutes in the dark and analyzed by flow cytometry(FACSCalibur, Beckton Dickinson).

Northern Blots. Normal human skin fibroblasts were grown to confluencyin 100 mm culture dishes. Fresh media was added along with or without 2,20 and 200 μM of FAC for 24 hours. Total RNA was isolated using RNeasyMini Kit according to manufacturer's instructions, and 10 μg wereresolved by electrophoresis on formaldehyde-1% agarose gels. Recovery of185 and 28S rRNA was analyzed using ethidium-bromide staining and imageanalysis on an Gel Doc 1000 optical-system (BioRad, Calif.). RNA wastransferred onto Hybond-N membrane (Amersham) by capillary transfer in10xSSC and immobilized by UV crosslinking. Human elastin cDNArecombinant probe H-11 was radiolabeled with ³²P random primer methodand incubated overnight at 42° C. with the membrane in Miracle Hybsolution at a concentration of 2.5−5×10⁶ cpm/ml. Membrane was washed tohigh stringency and the bound radioactivity was visualized byautoradiography and quantified by scanning densitometry (Gel Doc 1000).RNA loading and transfer were evaluated by probing with a glyceraldehydephosphate dehydrogenase (GAPDH) cDNA probe to which relative elastinmRNA values were normalized.

Quantitative TaqMan RT-PCR. To confirm the expression level of elastinmRNA in the presence of 2, 20, and 200 μM FAC obtained by Northern blotanalysis we also conducted quantitative RT-PCR. In order to assess theeffect of iron on elastin mRNA stability parallel quadruplicate cultureswere grown to confluency in 100 mm dishes. Media were then changed,supplemented with 60 μM of transcription blocker, DRB and cultures weremaintained in the presence or absence of 20 and 200 μM FAC for 0, 6, 12and 24 hours. Total RNA was extracted using the RNeasy Mini Kit,according to manufacturers instructions, at indicated time points. Thereverse transcriptase reaction was performed using 1.5 μg of total RNA,oligo(dT)'s and the SuperScript First-Strand synthesis system(Invitrogen Life Technologies) according to manufacturer's instructions.

Elastin mRNA levels was measured by real-time quantitative PCR methodperformed on the ABI PRISM 7700 Sequence Detection System (AppliedBiosystems, Foster City, Calif.). For each treatment two distinctamplifications were carried out in parallel in order to amplify elastincDNA and GAPDH cDNA. The amplification reactions were performed in 25 μlvolumes containing 30 ng of cDNA per treatment in triplicate, 12.5 μl of2× TaqMan Universal PCR Master Mix (Applied Biosystems), and 1.25 μl of20× Assays-on-Demand Gene Expression probe for elastin (AppliedBiosystems) or TaqMan GAPDH probe (Applied Biosystems). Elastin mRNAlevels from each treatment was normalized to the corresponding amount ofGAPDH mRNA levels. Water controls and samples without PCR mixtures wereset up to eliminate the possibility of significant DNA contamination.Final results were expressed as the mean of two independent experiments.

One-step RT-PCR. In order to further confirm the effect of iron onelastin mRNA levels, confluent normal human skin fibroblast cultureswere treated with or without intracellular ferric iron chelator, 20 μMDFO in the presence or absence of 20 μM FAC for 24 hours. Total RNA wasextracted using the RNeasy Mini Kit, according to manufacturersinstructions, and 1 μM of total RNA was added to each one step RT-PCR(Qiagen OneStep RT-PCR Kit) and reactions were set up according tomanufacturers instructions in a total volume of 25 μl. The reversetranscription step was performed for elastin and β-actin reactions at 50° C. for 30 minutes followed by 15 minutes at 95 ° C. The elastin PCRreaction (sense primer: 5 ′-GGTGCGGTGGTTCCTCAGCCTGG-3 ′ (SEQ ID NO: 50),antisense primer: 5′-GGCCTTGAGATACCC -AGTG-3 ′ (SEQ ID NO: 51); designedto produce a 255bp product) was performed under the followingconditions: 25 cycles at 94 ° C. denaturation for 20 s, 63 ° C.annealing for 20 s, 72 ° C. extension for 1 min; 1 cycle at 72 ° C.final extension for 10 min.

The β-actin PCR reaction (sense primer: 5 ′-GTCAGAAGGATTCCCTATGTG -3 ′(SEQ ID NO: 52), antisense primer: 5′-ATTGCCCAATGGTGATGACCTG -3′ (SEQ IDNO: 53); designed to produce a 615 bp product) was performed under thefollowing conditions: 25 cycles at 94 ° C. denaturation for 60 s, 60 °C. annealing for 60 s, 72 ° C. extension for 120 s; 1 cycle at 72 ° C.final extension for 10 min. 5 μl samples of the elastin and β-actin PCRproducts from each reaction were ran on a 2% agarose gel andpost-stained with ethidium bromide. The amount of elastin mRNA wasstandardized relative to the amount of β-actin mRNA.

Data Analysis. In all biochemical studies quadruplicate samples in eachexperimental group were assayed in two separate experiments. Mean andstandard deviations (SD) were calculated for each experimental group andstatistical analyses were carried out by ANOVA, P value of less than0.05 (p<0.05) was considered significant.

Results.

Low and High Doses of Iron Produce Opposite Effects on Production ofInsoluble Elastin. Low concentrations of iron 2-20 μM (supplied as FAC)relevant to physiological concentrations of mammalian serum iron (10-30μM), and then higher concentrations (100 and 200 μM) relevant to ironoverload were tested. Immunostaining of confluent fibroblast cultureswith anti-elastin antibody revealed that 3-day-long treatment with 2 and20 μM of iron significantly increased the production of elastic fibersover control levels (FIG. 7A). Interestingly, raising iron concentrationto 100 μM did not induce better elastin deposition then treatment with20 and treatment with 200 μM of iron dragged elastin deposition back tothe control levels. Metabolic labeling of cultured fibroblastsmaintained in 10% FBS (left panel) or in serum free medium (right panel)with [³H]-valine followed by quantitative assays of insoluble elastinconfirmed the results obtained with immunocytochemistry (*P<0.05) (FIG.7B). However, the net deposition of [³H]-valine-labeled insolubleelastin in cultures treated with 100 and 200 μM of iron wassignificantly lower than in cultures treated with 20 μM iron (**P<0.05).Results of parallel experiments measuring the incorporation of[³H]-thymidine demonstrated that the detected stimulation onelastogenesis in cultures treated with low iron concentrations was notdue to increased cellular proliferation rate and that the reverse effectobserved at higher concentrations of iron was not due to cellularcytotoxicity (FIG. 7C). Specifically, assessment of [³H]-thymidineincorporation demonstrates that cells treated with high doses of iron(100 μM and 200 μM) proliferate with a significantly higher rate thanuntreated cells (*P<0.05). Results of biochemical assays are expressedas the mean±SD derived from two separate experiments in which eachexperimental group had quadruplicate cultures.

Since the net production of elastic fibers depend on the coordinatedexpression of multiple factors, the expression of three major factorsfacilitating elasogenesis by immunoflourecent microscopy after exposureof normal human skin fibroblasts to low (20 μM) and high (200 μM) ironconcentrations was tested. In contrast to elastin, the immunodetectablelevels of fibrillin-1, a major component of fibrillar scaffold, theelastin binding protein (EBP), required for normal tropoelastinsecretion and extracellular assembly, and lysyl oxidase the enzymeresponsible for elastin cross-linking, were not changed in culturestreated with 20 and 200 μM of iron (data not shown).

The Influence of Iron on Elastin mRNA Levels and Message Stability.Since incubation of fibroblasts with low (2-20 μM) and high (200 μM)iron concentrations induced opposite effects on the net deposition ofinsoluble (extracellular) elastin, and that 2-200 μM iron concentrationsdid not stimulate elastolytic activity of serine proteinases (data notshown), the level on which fluctuations in iron level would affectelastogenesis was targeted for identification. Results of the followingseries of experiments demonstrate that low and high iron concentrationsinduced opposite effects in the neosynthesis of (metabolically labeled)immunoprecipitable tropoelastin that were proportional to the reportedchanges in the net deposition of insoluble elastin (FIG. 8A). Culturestreated for 72 hours with 2 and 20 μM iron (FAC) syntesize more[³H]-valine-labeled tropoelastin than untreated counterparts (*P<0.05).Cultures treated with higher iron concentrations (100 and 200 μM)demonstrated lower tropoelastin production as compared to those treatedwith 20 μM (**P<0.05).

These observations indicate that iron might regulate the earliest stagesof elastogenesis, transcription of elastin gene and/or elastin messagestability. Indeed, results of northern blot hybridization with elastincDNA probe (corrected for GAPDH mRNA levels) revealed a dose-dependentincrease in elastin mRNA levels in cultures incubated for 24 hours inthe presence of 2 and 20 μM iron. This trend was abolished and returnedback to control values in cultures treated with 200 μM of iron (FIG. 2B,left panel). We further examined elastin gene expression under sameexperimental conditions by quantitative real-time RT-PCR analysis. Thisconfirmed a substantial (˜3-fold) increase in elastin mRNA levels incultures treated for 24 hours with 20 μM of iron and a significantreduction in tropoelastin mRNA in cultures maintained in the presence of200 μM of iron (FIG. 2B, right panel). Thus, results of both experimentsdemonstrated that different concentrations of iron may differentlyaffect the steady-state levels of tropoelastin mRNA (**P<0.05).

The intensity of elastin message signal detected by Northern blottingwas assessed by densitometry after normalization to GAPDH message levelsand the corresponding values are shown in the bar graph in arbitraryunits. Elastin mRNA levels assessed by TaqMan real time PCR analysiswere normalized to the corresponding levels of GAPDH mRNA and expressedas a percentage of untreated control values.

Since steady-state mRNA levels reflect the balance between transcriptionefficiency and message decay, we further studied whether fluctuations iniron concentration may affect elastin mRNA stability. The stability ofelastin message was determined in fibroblasts cultures simultaneouslyincubated with 60 μM of DRB (a transcriptional inhibitor) in thepresence or absence of either 20 or 200 μM of iron during a 24 hour timecourse period (for 0, 6, 12, and 24 hours). At indicated time pointstotal RNA was extracted and subjected to quantitative TaqMan RT-PCRanalysis. The results are expressed as the mean±SD from two separateexperiments conducted in quadruplicate cultures.

The relative decay kinetics of elastin mRNA (quantified by real timeRT-PCR) was the same in control and 20 μM iron treated cultures, withhalf-life of ˜16 hours (FIG. 2C). In contrast, 200 μM iron treatedcultures demonstrated a rapid decrease in elastin mRNA level (about 2.5fold decrease), which reached its half-life just after ˜6-hourincubation (FIG. 2C). These observations suggested that the treatmentwith high iron concentrations induce a decay in elastin mRNA levels.

Intracellular Iron Levels Influence Elastin Production. Since theaddition of low iron concentrations (up to 20 μM) to the culture mediainduced a ˜3-fold increase in elastin mRNA steady-state levels andsubsequent increase in elastic fiber formation, further testing todetermine whether this effect is specifically dependent on intracellulariron was conducted. A highly specific membrane permeable ferric ironchelator, DFO, which have been shown to deplete intracellular pools offree iron was utilized. Results of immunocytochemistry (FIG. 9A),quantitative assay of newly deposited (metabolically labeled) insolubleelastin (FIG. 9B), and one step-RT-PCR analysis assessing elastin mRNAlevels (FIG. 9C), demonstrated that chelating intracellular iron incultured fibroblasts with 20 μM of DFO significantly reduced elastinmRNA levels and consequent elastic fibers deposition, as compared tountreated control. Simultaneous treatment of cultured fibroblasts withequimolar amounts (20 μM) of ferric iron and DFO abolished the ironinduced increase in elastin mRNA levels and elastin deposition (FIG. 9).Cumulatively, these data indicate that chelatable intracellular ironfacilitates normal expression of elastin gene and the consequentproduction of insoluble elastin.

The Effect of Iron on the Production of Intracellular ROS. It has beenwell established that iron has the capacity to generate ROS through theFenton reaction, and that ROS acting as second messengers may inducespecific intracellular signaling pathways. Tests to determine whetherdifferent iron concentrations utilized in this study may affect theproduction of ROS in normal human skin fibroblasts were conducted. Bothfluorescent microscopy and flow cytometry measuring intracellular levelsof ROS with a specific fluorescent probe, showed that cells incubatedwith 2-40 μM of iron produced the same amount of ROS as untreatedcontrols. In contrast, the addition of higher concentrations of iron(100-400 μM) to the culture medium induced a dose dependant increase inROS production (FIG. 10). Representative micrographs FIG. 10(A) andresults of flow cytometric analysis FIG. 10(B) show that fibroblaststreated with high concentrations of iron (100-400 μM FAC) produce moreROS (detected with CM-H₂DCFDA fluorescent probe) than untreated controlsand cells incubated with low iron concentration (2-20 μM FAC). Theresults of flow cytometric analysis are expressed as percentage ofpositive cells. Exclusion of the fluorescent probe, CM-H₂DCFDA, andaddition of 0.01% hydrogen peroxide represents the negative and positivecontrol, respectively.

Scavenging of Intracellular Hydroxyl Radical Reverts inhibition ofElastin Production in Cells Treated with High Concentration of iron.Since the above results indicate that the decrease in elastogenesis incells treated with high concentrations of iron coincide with an increasein the production of intracellular ROS, a pathophysiological linkbetween these two effects was anticipated. Results of next series ofexperiments confirmed this hypothesis. Treatment of cultured fibroblastswith 200 μM of iron and DMTU, the membrane permeable scavenger ofhydroxyl radicals, reversed the inhibitory effect of 200 μM irontreatment on elastin deposition (FIG. 5). In fact, 200 μM iron treatmentin the presence of DMTU produced almost a 2-fold increase in elastinproduction as compared to cultures treated with 200 μM iron alone. Asimilar effect in cultures simultaneously treated with 200 μM iron andthe membrane impermeable antioxidants, catalase and SOD (data not shown)and the membrane permeable SOD mimetic, Tempol (FIG. 11) were notobserved. Pre-treatment of cells with any of the four antioxidants priorto the addition of 20 μM of iron did not change the stimulatory effecton elastin deposition (data not shown). These results further indicatethat 20 μM iron treatment does not stimulate intracellular ROSproduction.

Mammalian cells maintain steady levels of metabolically active iron,also referred as the chelatable iron pool or labile iron pool (LIP),through the regulation of iron uptake and storage, which is critical tomaintaining normal cellular iron requirements. It has been shown thatcells treated with lower than 25 μM of iron (supplied as FAC) are ableto maintain an equilibrium between LIP and iron bound to ferritinwithout a disturbance in cellular metabolism. Results of the present invitro study demonstrate, for the first time, that treatment of normalhuman skin fibroblasts with such concentrations of iron, can up-regulatetropoelastin synthesis and its final extracellular deposition intoelastin fibers. Importantly, these low iron concentrations did not causeany increase in cellular proliferation rate (FIG. 7A). On the otherhand, treatment of fibroblasts with elevated iron concentrations(100-200 μM FAC) slightly stimulated cellular proliferation but failedto further stimulate elastin production and in fact elicited aninhibitory effect.

It is becoming increasingly evident that fluctuations in iron levels caninfluence the expression of various genes through non-iron responsiveelements (IRE)-mediated changes. Since treatment of cultured fibroblastswith low iron concentrations (2-20 μM) caused 2-3 fold increase in theelastin mRNA level (FIG. 8B) and that the elimination of the LIP bytreatment with a highly specific intracellular ferric iron chelator,DFO, led to a significant decrease in elastin mRNA levels and consequentelastin deposition (FIG. 9), it may be concluded that low intracellularconcentrations of chelatable iron may facilitate normal elastogenesis.This data strongly indicate a new level of complexity to the poorlyexplored area of elastin gene regulation. However, the preciseiron-dependent mechanism responsible for up-regulation of elastin genetranscription remains to be elucidated.

Using the analogy to the iron-dependent mechanism suggested for theactivation of other genes such as PKC-β, certain iron-responsivetranscriptional regulatory elements could be located within the elastin5′-flanking region. However, to date only one true activating sequencehas been identified within the elastin promoter, the nuclear factor-1(NF-1) binding sequence, which upon the interaction with one of NF-1family members can directly activate elastin gene transcription (16). Inseparate studies a newly identified nuclear protein, pirin, has beenshow to bind to NF-1 and was proposed as a functional cofactor forregulating gene transcription at the level of DNA complexes. Since pirinhas recently been demonstrated to contain an iron binding domain that isrequired for its function, the iron-induced increase in elastin messagelevel may result from the pirin-dependent activation of NF-1 andconsequent upregulation in elastin gene transcription. However, morestudies are needed to confirm this hypothesis.

Results of the study provide the anticipated experimental evidence thatthe expansion of the intracellular LIP in cultured fibroblasts, treatedwith high concentrations of iron, resulted in a significant rise inintracellular levels of hydroxyl radicals, and the consequent decreasein elastic fiber formation. The fact that scavenging intracellularhydroxyl radicals with DMTU induced by 200 μM iron treatment leads torestoration of elastin deposition (˜2-fold increase over untreatedcontrol, FIG. 11), confirms the hypothesis that iron overload may impairelastogenesis.

It has been previously documented that ROS may alter the expression ofcertain genes by interfering with message stability. The present dataprovide evidence that the iron-dependent generation of ROS indeedcoincide with a decrease in the stability of elastin mRNA (FIGS. 8C and11). Although several mechanisms for regulating the stability of mRNAshave been described, only a few have been well characterized. Ingeneral, removal of 5′-cap structures or 3′-polyadenosine tails areconsidered to lead to rapid degradation of messages. Sequence elementsin the 3′-untranslated region (3′-UTR) have also been implicated inregulation of the stability of many mRNAs. Although the stability ofelastin mRNA appears to be an important factor in regulating theexpression of this protein, which has been reported to be affected byTGF-β, phorbol esters, and vitamin D, details of the mechanism of thisregulation are still not understood.

Conserved GA-rich sequences present in elastin's 3′-UTR have been shownto be an important element in the regulation of elastin mRNA stability.The presence of this sequence has been shown to be particularlysusceptible to RNase attack when this site is not protected by yetunidentified binding protein factor. We speculate that ROS might alterthe binding of this putative protein to the GA-rich sequence in 3′-UTRof elastin mRNA, and consequently allow RNase to attack. Alternatively,elastin mRNA might be directly affected by oxidants or oxidant-dependentsignaling molecules stimulating its degradation.

Presented data clearly indicate that iron overload-induced oxidativestress interferes with elastogenesis. Importantly, the inhibitory effectof free radicals on elastogenesis can be minimized or eliminated byutilization of cell membrane permeable antioxidants.

The data also indicates the existence of parallel mechanism, in which anexcess of intracellular chelatable iron induce the formation of freeradicals that through unknown molecular manner, down-regulate elastinmessage stability and consequently decrease elastogenesis (FIG. 6). Anapparent balance between these two iron-dependent mechanisms mayconstitute a novel level of complexity regulating normal elastogenesis.A disturbance of this balance, caused either by increased levels of freeiron or chelation of intracellular iron, may result in impaired elastinproduction as observed in human hemolytic disorders. FIG. 12. Adepiction of two parallel iron-dependent mechanisms that may modulateelastin mRNA levels and consequently affect the net production ofelastin. The intracellular chelatable iron binds to the transcriptionfactor or cofactor, which stimulates a specific cis element within theelastin promoter region and, in turn, up-regulate transcription ofelastin mRNA. On the other hand, an excess of intracellular chelatableiron also induces production of reactive oxygen species (ROS) thatreduce the stability of newly transcribed elastin mRNA.

EXAMPLE 8

Materials and Methods. Organ cultures of explants were derived fromsurgical biopsies of human skin. In order to further test whether thereagents would penetrate into skin tissue and induce elastogenic effect,skin biopsies (taken from sun-protected buttock area) derived from fourwomen (age 35 to 55 years old) were cut into small (0.5 mm) pieces andplaced on top of metal grids immersed in the culture medium containing5% FBS and maintained for 7 days in the presence and absence of 10 μMMnSO₄ and 20 μM FAC. All organ cultures were fixed in 1% bufferedformalin and their transversal histological sections were stained withMovat pentachrome method to visualize major components of extracellularmatrix, including elastic fibers.

Results. The results indicate that even in control cultures, kept onlyin medium with 5% fetal bovine serum, there was activation of cellslocated in the stratum basale of the epidermis that resulted inproliferation and migration of these cells not only into the epidermis,but also into the papillary dermis. Those cells migrating down into thedermis demonstrated positive immunostaining for vimentin (marker oftheir differentiation toward fibroblast phenotype) and for PCNAproliferative antigen (FIG. 13). As shown in FIG. 13, transversalsections of skin biopsy maintained in organ culture for 7 days in thepresence and absence of 10 μM MnSO₄ and 20 μM FAC. Histological sectionson the left column show immunolocalization of PCNA mitogenic antigenthat is indicative of actively proliferating dermal fibroblasts.Histological sections on the right column show immunolocalization ofvimentin which is indicative of fibroblastic type cells. Those migratingcells were surrounded by single short elastic fibers. Cultures treatedadditionally either with 10 μM MnSO₄ or 20 μM FAC demonstrated higherthan control level of agitation and migration of stratum basale-derivedcells with fibroblastic phenotype. These cells penetrated deeper intodermis and were surrounded with networks of new elastic fibers. Asdemonstrated in FIG. 14, even lower magnification (×200) demonstrateddeposition of new elastic fibers in both the papillary and reticulardermis. FIG. 14 is representative histological sections from a skinbiopsy derived from a 45 year-old female. Sections were maintained inorgan culture in the presence or absence of 10 μM MnSO₄ and 20 μM FACfor 7 days then fixed and stained with Movat's Pentachrome for elasticfibers. Medium-power magnification (×400) revealed that MnSO₄ stimulatedproduction of long elastic fibers primarily running perpendicular to theepidermis whereas FAC induced deposition of shorter elastic fibersprimarily running parallel to the epidermis. High-power magnification(×600) allowed for better visualization of the enhanced infiltration ofcells that may represent the first generation of differentiating cellsderived from pluri-potential stem cells located in stratum basale. Organcultures treated with both MnSO₄ and FAC seem to contain more suchactivated cells.

Factors present in serum may initiate the differentiation of dermal stemcells toward fibroblasts, but both MnSO₄ and FAC acceleratedifferentiation of these new fibroblasts and stimulate their migratoryabilities and elastogenic potential. Since the pre-existing fibroblastsalready residing in the deep dermis did not demonstrate any signs ofmitotic activation nor elastogenesis, only newly differentiatedfibroblasts derived from the stratum basale may be stimulated to producenew elastic fibers. Small molecules of MnSO₄ and FAC that penetratethrough the stratum corneum have a strong probability of interactingwith stem cells in the stratum basale and then initiating theirdifferentiation into fibroblasts. Further, migration of these newlydifferentiated cells into the papillary and reticular dermis and theirdeposition of new elastic fibers seem to constitute a critical conditionfor rejuvenation of the skin. Importantly the data indicates that thiseffect can be induced in skin of adult and even ageing patients.Interestingly this observation may additionally confirm the paradigmthat fully differentiated fibroblasts are no longer capable to resumeproduction of elastic fibers and indicate for the first time that onlytreatments, as presented here, specifically designed for stimulation ofundifferentiated cells into fibroblastic phenotype may produce elasticfibers during the relatively short time after their fulldifferentiation. Since elastic fibers are much more durable than othercomponents of extracellular matrix, the therapeutic or cosmetic approachto restoring elastin fibers in aged skin as presented herein will likelyproduce long lasting and cosmetically acceptable improvement of theadult human skin.

Although the present invention has been described in considerable detailwith reference to certain preferred embodiments thereof, other versionsare possible. Therefore the spirit and scope of the appended claimsshould not be limited to the description and the preferred embodimentsdisclosed herein.

What is claimed is:
 1. A therapeutic composition comprising: one or moreof a peptide consisting of GXXPG (SEQ ID NO: 54), wherein each X isindependently a natural amino acid, 3-hydroxyproline, or4-hydroxyproline; and a divalent manganese based compound or trivalentiron based compound, wherein the divalent manganese based compound has aconcentration of about 0.5 μM to about 25 μM, and wherein the trivalentiron based compound has a concentration of about 5 μM to about 75 μM;and wherein the therapeutic composition is for topical administration.2. The composition of claim 1, wherein the divalent manganese basedcompound is manganese-PCA.
 3. The composition of claim 2, wherein themanganese-PCA has a concentration of about 0.5 μM to about 5 μM.
 4. Thecomposition of claim 1, wherein the trivalent iron based compound isferric ammonium citrate or ferric chloride.
 5. The composition of claim1, further including an elastic tissue digest.
 6. The composition ofclaim 5, wherein the elastic tissue digest comprises a mixture ofelastin peptides.
 7. The composition of claim 1, further includingepitopes, cytokines and growth factors.
 8. The composition of claim 1,further including an excipient.
 9. The composition of claim 1, whereinsaid composition is selected from the group consisting of an emulsion,lotion, spray, aerosol, powder, ointment, cream, mouthwash, toothpaste,foam and gel.
 10. The composition of claim 1, further including one ormore additives chosen from the group consisting of tropoelastinexcretion inducers, tropoelastin synthesis stimulators, compoundsinducing deposition on microfibril scaffolds, compounds which inducelysyl oxidase synthesis, and copper ion sources.
 11. The composition ofclaim 1, further including retinoic acid.
 12. A therapeutic skin careproduct comprising: a peptide consisting of GXXPG (SEQ ID NO: 54),wherein each X is independently a natural amino acid, 3-hydroxyproline,or 4-hydroxyproline; and a therapeutically effective amount of atrivalent iron based compound or divalent manganese based compound,wherein the divalent manganese based compound has a concentration ofabout 0.5 μM to about 25 μM, and wherein the trivalent iron basedcompound has a concentration of about 5 μM to about 75 μM; and whereinthe product is for topical administration.
 13. The therapeutic skin careproduct of claim 12, wherein said trivalent iron based compoundcomprises ferric ammonium citrate or ferric chloride.
 14. Thetherapeutic skin care product of claim 12, wherein the divalentmanganese based compounds is selected from the group consisting ofmanganese-PCA, manganese chloride, manganese gluconate, manganesesulfate, manganese nitrate and manganese ascorbate.
 15. The compositionof claim 1, wherein the GXXPG peptide (SEQ ID NO: 54) comprises asequence selected from the group consisting of GAAPG (SEQ ID NO: 1),GVVPG (SEQ ID NO: 2), GGGPG (SEQ ID NO: 3), GLLPG (SEQ ID NO: 4), GIIPG(SEQ ID NO: 5), GSSPG (SEQ ID NO: 6), GTTPG (SEQ ID NO: 7), GCCPG (SEQID NO: 8), GMMPG (SEQ ID NO: 9), GFFPG (SEQ ID NO: 10), GYYPG (SEQ IDNO: 11), GWWPG (SEQ ID NO: 12), GDDPG (SEQ ID NO: 13), GNNPG (SEQ ID NO:14), GEEPG (SEQ ID NO: 15), GQQPG (SEQ ID NO: 16), GRRPG (SEQ ID NO:17), GHHPG (SEQ ID NO: 18), GKKPG (SEQ ID NO: 19), GPPPG (SEQ ID NO:20), G3Hyp3HypPG (SEQ ID NO: 21) and G4Hyp4HypPG (SEQ ID NO: 22). 16.The composition of claim 1, wherein the trivalent iron based compoundhas a concentration of about 5 μM to about 50 μM.
 17. The composition ofclaim 1, wherein the trivalent iron based compound has a concentrationof 20 μM.
 18. The therapeutic skin care product of claim 12, wherein theGXXPG peptide (SEQ ID NO: 54) comprises a sequence selected from thegroup consisting of GAAPG (SEQ ID NO: 1), GVVPG (SEQ ID NO: 2), GGGPG(SEQ ID NO: 3), GLLPG (SEQ ID NO: 4), GIIPG (SEQ ID NO: 5), GSSPG (SEQID NO: 6), GTTPG (SEQ ID NO: 7), GCCPG (SEQ ID NO: 8), GMMPG (SEQ ID NO:9), GFFPG (SEQ ID NO: 10), GYYPG (SEQ ID NO: 11), GWWPG (SEQ ID NO: 12),GDDPG (SEQ ID NO: 13), GNNPG (SEQ ID NO: 14), GEEPG (SEQ ID NO: 15),GQQPG (SEQ ID NO: 16), GRRPG (SEQ ID NO: 17), GHHPG (SEQ ID NO: 18),GKKPG (SEQ ID NO: 19), GPPPG (SEQ ID NO: 20), G3Hyp3HypPG (SEQ ID NO:21) and G4Hyp4HypPG (SEQ ID NO: 22).
 19. The therapeutic skin careproduct of claim 12, wherein the trivalent iron based compound has aconcentration of about 5 μM to about 50 μM.
 20. The therapeutic skincare product of claim 12, wherein the trivalent iron based compound hasa concentration of 20 μM.